SCHEMBL31301601

SCHEMBL31301601

Clc1cccc(-c2c[nH]c3ncnc(N4CCC(c5ccccc5)CC4)c23)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 16/20 0.77
STK3 Q13188 13/20 0.77
STK4 Q13043 11/20 0.77
CDC7 O00311 2/20 0.63
MARK3 P27448 2/20 0.63
PLK4 O00444 1/20 0.63
CHEK1 O14757 1/20 0.63
AURKA O14965 1/20 0.63
PDPK1 O15530 1/20 0.63
JAK2 O60674 1/20 0.63
ROCK2 O75116 1/20 0.63
PAK4 O96013 1/20 0.63
CHEK2 O96017 1/20 0.63
EGFR P00533 1/20 0.63
NTRK1 P04629 1/20 0.63
PRKCG P05129 1/20 0.63
INSR P06213 1/20 0.63
LCK P06239 1/20 0.63
FYN P06241 1/20 0.63
CDK1 P06493 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301556 0.87 LRRK2 (1.00) LRRK2STK3STK4CDC7MARK3
SCHEMBL31301647 0.86 LRRK2 (0.82) LRRK2STK3STK4CDC7MARK3
SCHEMBL31301679 0.85 LRRK2 (0.73) LRRK2STK3STK4CDC7MARK3
SCHEMBL31301675 0.85 LRRK2 (0.80) LRRK2STK3STK4CDC7MARK3
SCHEMBL31301604 0.85 LRRK2 (0.98) LRRK2STK3STK4CDC7MARK3
SCHEMBL31301676 0.85 LRRK2 (0.93) LRRK2STK3STK4CDC7MARK3
SCHEMBL31301652 0.84 LRRK2 (1.00) LRRK2STK3STK4CDC7MARK3
SCHEMBL3953561 0.84 LRRK2 (1.00) LRRK2STK3STK4CDC7MARK3
SCHEMBL30295750 0.84 LRRK2 (0.77) LRRK2STK3STK4CDC7MARK3
SCHEMBL30295911 0.84 LRRK2 (0.77) LRRK2STK3STK4CDC7MARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF STK3, STK4, STK36 LRRK2 210/4885STK3 1/4885STK4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.